Does Rallies show 13F holders for XENE?

Yes. Rallies tracks hedge fund and 13F ownership data for XENE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is XENE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XENE. It does not provide personalized investment advice.

XENE (Xenon Pharmaceuticals Inc) Stock Analysis - Hedge Fund Holdings

Xenon Pharmaceuticals Inc (XENE) is a publicly traded Healthcare sector company. As of May 20, 2026, XENE trades at $54.67 with a market cap of $5.19B and a P/E ratio of -12.52. XENE moved +1.17% today. Year to date, XENE is +30.84%; over the trailing twelve months it is +73.97%. Its 52-week range spans $26.74 to $63.95. Analyst consensus is strong buy with an average price target of $78.37. Rallies surfaces XENE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns XENE stock?

Hedge funds tracked by Rallies that own XENE include Orbimed Advisors, Redmile Group, Duquesne Family, Eisler Capital, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Xenon Pharmaceuticals Inc.

XENE Key Metrics

Key financial metrics for XENE
Metric	Value
Price	$54.67
Market Cap	$5.19B
P/E Ratio	-12.52
EPS	$-4.36
Dividend Yield	0.00%
52-Week High	$63.95
52-Week Low	$26.74
Volume	860.40K
Avg Volume	0
Revenue (TTM)	$7.50M
Net Income	$-345.91M
Gross Margin	0.00%

Top Hedge Funds Holding XENE

Orbimed Advisors holds 1.06M shares of XENE, changed +137.02% as of Mar 31, 2026.
Redmile Group holds 262.67K shares of XENE, changed +96.20% as of Mar 31, 2026.
Duquesne Family holds 238.60K shares of XENE, changed +0.00% as of Mar 31, 2026.
Eisler Capital holds 22.02K shares of XENE, changed +32.21% as of Jun 30, 2024.
Centerbook Partners holds 14.77K shares of XENE, changed -40.12% as of Sep 30, 2025.

Latest XENE News

Xenon Secures $1.3B Cash Runway, Eyes Q3 2026 NDA After 53.2% Seizure Reduction — May 7, 2026
Xenon rises as Phase 3 azetukalner focus returns ahead of May catalysts — May 4, 2026
Xenon Pharmaceuticals Secures US$747.5M Financing After Phase 3 Success of AZK — May 1, 2026
Xenon climbs as Phase 3 azetukalner momentum builds and funding optionality stays in focus — Apr 29, 2026
Xenon slips as investors sell the news after detailed Phase 3 azetukalner data — Apr 20, 2026

Recent XENE Insider Trades

KENNEY CHRISTOPHER JOHN sold 1.41K (~$77.87K) on Mar 13, 2026.
DiFabio Andrea sold 1.34K (~$74.11K) on Mar 13, 2026.
MORTIMER IAN sold 7.31K (~$403.58K) on Mar 13, 2026.

XENE Analyst Consensus

19 analysts cover XENE: 0 strong buy, 19 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $78.37.

Common questions about XENE

Who owns XENE stock?: Hedge funds tracked by Rallies that own XENE include Orbimed Advisors, Redmile Group, Duquesne Family, Eisler Capital, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Xenon Pharmaceuticals Inc.
Does Rallies show 13F holders for XENE?: Yes. Rallies tracks hedge fund and 13F ownership data for XENE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is XENE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XENE. It does not provide personalized investment advice.